Net Income (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of net income per share attributable to common stockholders

For periods in which the Company reports net losses, basic and diluted net loss per share are the same because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2022		2021		2022
Numerator:
Net income (loss)	$	29,113	$	(56,223)	$	76,499	$	(53,402)






Denominator:
Weighted-average common shares outstanding used to calculate net income (loss) per share, basic	79,392,600		81,672,099		76,586,395		83,236,131
Weighted-average effect of dilutive securities	16,664,610		—		17,578,930		—
Weighted-average common shares outstanding used to calculate net income (loss) per share, diluted	96,057,210		81,672,099		94,165,325		83,236,131

Net income (loss) per share, basic	$	0.37	$	(0.69)	$	1.00	$	(0.64)
Net income (loss) per share, diluted	$	0.30	$	(0.69)	$	0.81	$	(0.64)

Schedule of antidilutive securities excluded from computation of earnings per share

The following securities were excluded from the computation of diluted net income (loss) per share for the periods presented, because including them would have been anti-dilutive. These amounts represent the number of instruments outstanding at the end of each respective period:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2021	2022	2021	2022

Options to purchase common stock	5,310	11,723,427	501,476	11,723,427
Unvested RSUs	214,481	4,679,719	896,131	4,679,719
Unvested PRSUs	—	687,500	—	687,500
Purchase rights committed under the ESPP	27,746	109,198	27,746	109,198

Convertible debt	2,318,078	2,318,078	2,318,078	2,318,078

Total	2,565,615	19,517,922	3,743,431	19,517,922